AbCellera Partners With PE Firms to Develop Antibody Drugs, Company Creation

Seeking AlphaMay 1 23:44

Institutional Owners May Consider Drastic Measures as AbCellera Biologics Inc.'s (NASDAQ:ABCL) Recent US$91m Drop Adds to Long-term Losses

Key Insights Given the large stake in the stock by institutions, AbCellera Biologics' stock price might be vulnerable to their trading decisions 50% of the business is held by the top 8 shareholders

Simply Wall StApr 22 18:42

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Business WireApr 9 00:05

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Business WireApr 4 04:05

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Yahoo FinanceMar 20 04:05

AbCellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions

AbCellera (NASDAQ:ABCL) and Biogen Inc. (NASDAQ:BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain fo

BenzingaMar 11 21:03